Skip to main navigation
Skip to search
Skip to main content
Oregon Health & Science University Home
Search content at Oregon Health & Science University
Home
Profiles
Research units
Core Facilities
Publications
Tardive dyskinesia
J. Gerlach
, D. E. Casey
Research output
:
Contribution to journal
›
Review article
›
peer-review
188
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Tardive dyskinesia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Tardive Dyskinesia
100%
Antidopaminergic
25%
Moderate Dose
12%
Striatum
12%
High Risk
12%
Dopamine
12%
Clozapine
12%
Etiological Factors
12%
Dopamine Receptor
12%
Substantia Nigra
12%
Treatment Duration
12%
Pathophysiological Mechanisms
12%
Treatment Length
12%
Parkinsonism
12%
Gradual Reduction
12%
Atypical Neuroleptics
12%
Drug Treatment
12%
Globus Pallidus
12%
Dyskinesia
12%
Akathisia
12%
Involuntary Movement
12%
Striatal Dopamine
12%
Treatment Principles
12%
Dystonia-parkinsonism
12%
Simple Correlation
12%
Minimal Risk
12%
Pharmacology, Toxicology and Pharmaceutical Science
Tardive Dyskinesia
100%
Antipsychotic
37%
Parkinsonism
25%
Typical Antipsychotic
25%
Pharmacotherapy
12%
Prevalence
12%
Syndrome
12%
Clozapine
12%
4 Aminobutyric Acid
12%
Dopamine Receptor
12%
Atypical Antipsychotics
12%
Erethism
12%
Dystonia
12%
Dyskinesia
12%
Akathisia
12%
Dopamine
12%
Etiology
12%
Neuroscience
Tardive Dyskinesia
100%
Antipsychotic
50%
Typical Antipsychotic
37%
Parkinsonism
25%
Gamma-Aminobutyric Acid
12%
Striatum
12%
Clozapine
12%
Dopamine Receptor
12%
Substantia nigra
12%
Globus pallidus
12%
Dyskinesia
12%
Dystonia
12%
Akathisia
12%
Dopamine
12%